(Bolded numbers represent the group of patients who had the highest expression of IL-33 during the times after relapse).</p
<p>Blue: 1<sup>st</sup> quartile, purple: 2<sup>nd</sup> quartile, pink: 3<sup>rd</sup> quartile, re...
<p>The expression of HLA-DR, HLA-I, HLA-E as well as the co-stimulatory molecules CD80, CD83 or CD86...
<p>PBMCs from GD patients (n = 40) and HCs (n = 30) were stimulated with recombinant IL-37 (100 ng/m...
(a-d) Longitudinal analysis of expression of IL-33 in each individual RRMS patients following a radi...
IL-33 expression levels were determined by PCR and normalized to expression levels of GAPDH. The X-a...
(a) Profile of IL-33 in patients showing highest level of expression of IL-33 at month 0, month 6–9 ...
The Y axis shows the different therapies patients were maintained on during the 12 month period afte...
ObjectiveWe tested the hypothesis that the expression of IL-33 in MS is dynamic and is likely to ref...
Flow cytometric study on the expression of IL-33 in CD14+ and CD14- population of PBMC at different ...
Correlation of IL-33 expression with expression of HDAC3 (left panel) or HDAC1 (right panel). The da...
OBJECTIVE:We tested the hypothesis that the expression of IL-33 in MS is dynamic and is likely to re...
a)IL-33 levels are correlated with expression of multiple genes during MS relapse and remission. mRN...
Cohort of RRMS patients after relapse treated with either Tecfidera or Beta Interferon who underwent...
<p>Scatter diagram displaying the protein levels of IL-33 and sST2 in the plasma of HFRS patients. C...
<p>Event-free survival (left) and incidence of relapse (right) of patients stratified according to F...
<p>Blue: 1<sup>st</sup> quartile, purple: 2<sup>nd</sup> quartile, pink: 3<sup>rd</sup> quartile, re...
<p>The expression of HLA-DR, HLA-I, HLA-E as well as the co-stimulatory molecules CD80, CD83 or CD86...
<p>PBMCs from GD patients (n = 40) and HCs (n = 30) were stimulated with recombinant IL-37 (100 ng/m...
(a-d) Longitudinal analysis of expression of IL-33 in each individual RRMS patients following a radi...
IL-33 expression levels were determined by PCR and normalized to expression levels of GAPDH. The X-a...
(a) Profile of IL-33 in patients showing highest level of expression of IL-33 at month 0, month 6–9 ...
The Y axis shows the different therapies patients were maintained on during the 12 month period afte...
ObjectiveWe tested the hypothesis that the expression of IL-33 in MS is dynamic and is likely to ref...
Flow cytometric study on the expression of IL-33 in CD14+ and CD14- population of PBMC at different ...
Correlation of IL-33 expression with expression of HDAC3 (left panel) or HDAC1 (right panel). The da...
OBJECTIVE:We tested the hypothesis that the expression of IL-33 in MS is dynamic and is likely to re...
a)IL-33 levels are correlated with expression of multiple genes during MS relapse and remission. mRN...
Cohort of RRMS patients after relapse treated with either Tecfidera or Beta Interferon who underwent...
<p>Scatter diagram displaying the protein levels of IL-33 and sST2 in the plasma of HFRS patients. C...
<p>Event-free survival (left) and incidence of relapse (right) of patients stratified according to F...
<p>Blue: 1<sup>st</sup> quartile, purple: 2<sup>nd</sup> quartile, pink: 3<sup>rd</sup> quartile, re...
<p>The expression of HLA-DR, HLA-I, HLA-E as well as the co-stimulatory molecules CD80, CD83 or CD86...
<p>PBMCs from GD patients (n = 40) and HCs (n = 30) were stimulated with recombinant IL-37 (100 ng/m...
DOI
Add to ORKG